ask the EMA oracle [Outliers]

posted by Ohlbe – France, 2011-10-06 18:31 (4582 d 23:15 ago) – Posting: # 7436
Views: 7,957

Dear D. Labes,

❝ A little bit curious for me is the underlined sentence. Taken literally it would not allow to exclude such profiles for the Test formulation :confused:.


My understanding is that this is precisely the idea ! Basically, if no concentration is measured after the reference product, EU regulators are ready to assume that the subject did not swallow the product. The reference formulation is considered to be reliable :-|
If the same situation happens after the test product, they consider that they cannot make the difference between a non-compliant subject and a deficient tablet. They will not take any chance.

Regards
Ohlbe

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
22,991 posts in 4,827 threads, 1,648 registered users;
60 visitors (1 registered, 59 guests [including 6 identified bots]).
Forum time: 17:47 CEST (Europe/Vienna)

If you don’t like something change it;
if you can’t change it, change the way you think about it.    Mary Engelbreit

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5